%0 Journal Article %A Jyoti Jain %A Suman Saurabh %A Akhil Dhanesh Goel %A Manoj Kumar Gupta %A Pankaj Bhardwaj %A Pankaja Ravi Raghav %T COVID-19 vaccine hesitancy among undergraduate medical students: results from a nationwide survey in India %D 2021 %R 10.1101/2021.03.12.21253444 %J medRxiv %P 2021.03.12.21253444 %X COVID-19 vaccine was launched in India on 16 January 2021, prioritizing health care workers which included medical students. We aimed to assess vaccine hesitancy and factors related to it among undergraduate medical students in India. An online questionnaire was filled by 1068 medical students across 22 states and union territories of India from 2 February – 7 March 2021. Vaccine hesitancy was found among 10.6%. Concern regarding vaccine safety and efficacy, hurried testing of vaccines prior to launch and lack of trust in government agencies predicted COVID-19 vaccine hesitancy. Risk perception regarding contracting COVID-19 vaccine reduced COVID-19 vaccine hesitancy as well as hesitation in participating in COVID-19 vaccine trials. Choosing between the two available vaccines (Covishield and Covaxin) was considered important by medical students both for themselves and their future patients. Covishield was preferred to Covaxin by students. Majority of those willing to take the COVID-19 vaccine felt that it was important for them to resume their clinical posting, face-to-face classes and get their personal life back on track. Around three-fourths medical students viewed that COVID-19 vaccine should be made mandatory for both health care workers and international travellers. Prior adult vaccination didn’t have an effect upon COVID-19 vaccine hesitancy. Targeted awareness campaigns, regulatory oversight of vaccine trials and public release of safety and efficacy data and trust building activities could further reduce COVID-19 vaccine hesitancy among medical students.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that no funding was received from any source for the study and preparation of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Institutional Ethics Committee of All India Institute of Medical Sciences (AIIMS) Jodhpur, India (Ref: AIIMS/IEC/2021/3438).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData upon which the study findings are based will be included in Supplementary file 1, along with the journal article upon final acceptance for publication. %U https://www.medrxiv.org/content/medrxiv/early/2021/03/12/2021.03.12.21253444.full.pdf